New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Q32 Bio Inc. (QTTB) vs Scribe Therapeutics Inc. (SCTX)

Q32 Bio Inc. and Scribe Therapeutics Inc. are both Biotechnology companies. Q32 Bio Inc. and Scribe Therapeutics Inc. are of similar size ($253.8M and $250.4M). Scribe Therapeutics Inc. has negative trailing earnings, so its P/E is not meaningful; Q32 Bio Inc. trades at 2.5×. Across the 4 metrics below, Q32 Bio Inc. leads on 3 and Scribe Therapeutics Inc. on 1.

Valuation

Metric QTTB SCTX Biotechnology median
P/E 2.49 n/m 8.49
P/S n/m 6.75 8.56
P/B 0.99 1.40 2.04
Price to free cash flow n/m — 23.84
EV/EBITDA 0.15 n/m 0.69
EV/Sales 0.78 0.02 8.00
Earnings yield 40.19% (80.87%) (35.81%)
Free cash flow yield (7.04%) — (25.41%)

Profitability

Metric QTTB SCTX Biotechnology median
Gross margin 100.00% — 70.18%
Operating margin 725.53% — 0.00%
Net margin 808.04% — 0.00%
Free cash flow margin 280.89% — 0.00%
Return on equity 23.96% — (51.58%)
Return on assets 18.17% — (45.91%)
Return on invested capital 0.00% — 0.00%

Growth

Metric QTTB SCTX Biotechnology median
Revenue growth (TTM) (307.33%) — 7.20%
EPS growth (last fiscal year) 136.78% — 29.04%
Revenue growth, 5-year CAGR — — 9.54%
Net income growth, 5-year CAGR — — 0.00%

Health

Metric QTTB SCTX Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 56.34 4.72 4.79
Net debt to EBITDA (2.21) — 1.01

Dividend

Metric QTTB SCTX Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric QTTB SCTX Biotechnology median
Market cap 253.75m 250.35m 150.57m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack